Virtual Town Hall Event

Advanced Molecular Techniques in Infectious Diseases: Case Studies in Mycology

A Virtual Town Hall Event – Stay Tuned for the Archived Version!

Did you attend the event?

Instructions for Credit To receive CE credit, learners must follow these steps after attending the activity:

Visit https://cme.partnersed.com/TownHall7212025
Complete the activity evaluation
Upon completion of all evaluation questions, your credit will be made available for download immediately.

For Pharmacists: Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Program Overview

Diagnosis of invasive fungal infections is often delayed, resulting in negative outcomes for many patients. Diagnostic delays are driven partially by failure to “think fungus” in appropriate scenarios. Additionally, the limitations of traditional fungal diagnostics also contribute to the delay in definitive fungal diagnosis. Recently, advances have been made in fungal diagnostics, including molecular techniques such as polymerase chain reaction (PCR) testing on various samples as well as metagenomic next-generation sequencing (mNGS) for RNA and DNA conducted on both blood and cerebrospinal fluid. Yet many questions remain in the clinical community about the performance characteristics of these advanced molecular tests in various populations and the interpretation of the test results to support clinical decision making. Join us for this live, interactive 1-hour accredited town hall, in which infectious diseases experts Dr Luis Ostrosky-Zeichner and Angel Desai discuss the appropriate use of advanced diagnostic techniques as part of an overall fungal diagnostic schema in pediatric hematology/oncology, intensive care, and immunocompromised host settings.

Target Audience

This initiative is intended for infectious diseases physicians, critical care physicians, hospitalists, intensivists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other health care providers responsible for the diagnosis and management of invasive fungal infections.

Educational Objectives

Upon completion of this activity, participants should be able to:

Recognize patients at risk for invasive fungal infections or manifesting clinical signs and symptoms, evaluating the pretest probability for various fungal diagnostic tests
Evaluate the benefits and limitations of advanced molecular techniques for fungal disease to inform treatment decisions
Appropriately use advanced molecular and mNGS techniques to enhance diagnostic accuracy of fungal infections

Program Agenda

Noon Introductions

12:04 pm Pediatric hematology/oncology patient

12:18 pm Intensive care unit patient

12:31 pm Patient with Immunocompromise

12:45 pm Panel Discussion and Q/A

1:00 pm Adjourn

Faculty

Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ (Chair)

Professor of Medicine and Epidemiology
Vice-Chair of Medicine for Healthcare Quality
Director of the Laboratory of Mycology Research
Division Chief at the Division of Infectious Diseases
McGovern Medical School (a part of UTHealth)
Houston, Texas

Angel Desai, MD, MPH

Associate Professor
Division of Infectious Diseases
Department of Internal Medicine
UC Davis Health
Sacramento, California

Disclosure of Conflicts of Interest

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Luis Ostrosky-Zeichner, faculty for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for Scynexis, Melinta, GSK, Pulmocide, F2G, Basilea, Viracor Eurofins, Gilead
Angel Desai, faculty for this educational activity, has no relevant financial relationships to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners and Terranova Medica, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education is 1 contact hour.

Continuing Pharmacy Education

Partners designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number – JA4008073-9999-25-187-L01-P

Type of Activity: Application

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

There is no fee for this activity.

Jointly provided by Partners and Terranova Medica, LLC.

MSGERC is providing content and distribution support.

This activity is supported by an independent educational grant from Karius.

For further information, contact Tom Davis by telephone (877-276-4523), or by email (tdavis@terranovamedica.com).